Jill Feldman: 40 years of research and care for Mark Kris
Jill Feldman, Co-Founder, EGFR Resisters, shared a post on X:
“I just heard huge news that needs to be celebrated!
Today marks 40 years of research and care for Dr Mark Kris. Dr Kris has been a champion for innovative research, playing a pivotal role in many advancements over the past 4 decades. His contributions to science have transformed lung cancer care nationally and internationally. Dr Kris has consistently pushed boundaries as a founder of the Lung Cancer Mutation Consortium and a pioneer in advocating for dose optimization, anti-nausea protocols before chemotherapy, and supportive care (when many considered side effects a trade-off for longer life).
He mentored generations of oncologists who now lead departments and run major trials. Most importantly, he gave hope to patients and families when there wasn’t much if any (many years).
Thank you, Dr. Kris, for your tireless efforts and dedication to improving survival and quality of life for people diagnosed with lung cancer and our families!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023